公开(公告)号：EP3177598A1

公开(公告)日：2017-06-14

申请号：EP15750269.1

申请日：2015-07-28

申请人： Institut National de la Santé et de la Recherche Médicale (INSERM) ,  Universite d'Auvergne Clermont I

发明人： DENIS, Claire ,  GAUMET, Vincent ,  VIDAL, Aurélien ,  AUZELOUX, Philippe ,  MADELMONT, Jean-Claude ,  MIOT-NOIRAULT, Elisabeth ,  CHEZAL, Jean-Michel

IPC分类号： C07D257/02 ,  C07D487/08 ,  C07F1/08 ,  A61P19/00

CPC分类号： C07D257/02 ,  C07D487/08 ,  C07F1/08

摘要： The present invention concerns compounds of formula (I):their process of preparation and compositions thereof. The present invention also concerns their use as diagnostic agent in PET imaging.

摘要翻译： 本发明涉及式（I）的化合物：它们的制备和它们的组合物的过程。 因此，本发明涉及它们作为在PET成像诊断剂的用途。

公开(公告)号：EP2925346A1

公开(公告)日：2015-10-07

申请号：EP13766995.8

申请日：2013-09-27

申请人： Universite d'Auvergne Clermont I

发明人： BRUGERE, Jean-François ,  BORREL, Guillaume ,  O'TOOLE, Paul William ,  MALPUECH-BRUGERE, Corinne ,  ALRIC, Monique

IPC分类号： A61K38/45 ,  A61P43/00 ,  A61P9/00 ,  A61P15/02 ,  A61K35/74 ,  C12N1/20

CPC分类号： A61K35/74 ,  A61K38/45 ,  C12N9/1007 ,  C12Y201/0125 ,  Y02A50/473

摘要： Composition containing a microorganism, preferably an
Archaea , expressing a TMA methyltransferase and a TMA methyl group acceptor corrinoid protein, capable of metabolizing trimethylamine (TMA) in the presence of hydrogen in a human cavity, such as the intestine or the vagina, for use as a medicament for treating, reducing or eliminating TMA at the level of the human cavity. In addition, a composition containing a TMA methyltransferase and a TMA methyl group acceptor corrinoid protein. These compositions are of use for treating trimethylaminuria, for treating vaginal fluids in the case of bacterial vaginosis and for reducing or eliminating odours due to TMA. These compositions are also of use for reducing the level of plasma TMAO, for preventing the formation of atheroma plaques and/or for preventing cardiovascular diseases.

摘要翻译： 组合物含有微生物，优选地在古细菌，表达TMA甲基和TMA甲基受体类咕啉蛋白，能够在人体腔室代谢在氢的存在下三甲胺（TMA）,:如肠或阴道的，用作 用于治疗，减轻或在人的腔体的水平消除TMA药物。 另外，含有一个TMA甲基和甲基受体TMA的组合物类咕啉蛋白。 这些组合物的使用，用于治疗Trimethylaminuria，对细菌性阴道病的情况下治疗阴道分泌液和因TMA减少或消除气味。 因此在使用的这些组合物是用于降低血浆TMAO的水平，为了防止动脉粥样硬化斑块的形成和/或用于预防心血管疾病。

公开(公告)号：EP2841402B1

公开(公告)日：2016-11-30

申请号：EP13725814.1

申请日：2013-04-19

申请人： Institut National de la Santé et de la Recherche Médicale ,  Laboratoires Cyclopharma ,  Universite d'Auvergne Clermont I

发明人： CHEZAL, Jean-Michel ,  RBAH-VIDAL, Latifa ,  BILLAUD, Emilie ,  AUZELOUX, Philippe ,  MADELMONT, Jean-Claude ,  VIDAL, Aurélien ,  MIOT-NOIRAULT, Elisabeth ,  PAPON, Janine ,  MAISONIAL, Aurélie

IPC分类号： C07B59/00 ,  C07D241/44 ,  C07D403/12 ,  C07F7/22

CPC分类号： A61K51/0459 ,  C07B59/002 ,  C07D241/44 ,  C07D403/12 ,  C07F7/2212

公开(公告)号：EP2841402A1

公开(公告)日：2015-03-04

申请号：EP13725814.1

申请日：2013-04-19

申请人： Institut National de la Santé et de la Recherche Médicale (INSERM) ,  Laboratoires Cyclopharma ,  Universite d'Auvergne Clermont I

发明人： CHEZAL, Jean-Michel ,  RBAH-VIDAL, Latifa ,  BILLAUD, Emilie ,  AUZELOUX, Philippe ,  MADELMONT, Jean-Claude ,  VIDAL, Aurélien ,  MIOT-NOIRAULT, Elisabeth ,  PAPON, Janine ,  MAISONIAL, Aurélie

IPC分类号： C07B59/00 ,  C07D241/44 ,  C07D403/12 ,  C07F7/22

CPC分类号： A61K51/0459 ,  C07B59/002 ,  C07D241/44 ,  C07D403/12 ,  C07F7/2212

摘要： The present invention relates to the compound of formula (I), in which R1 represents Sn(R)
3 , B(OH)
2 , B(OR)
2 , a halogen atom, NO
2 , a radionuclide or a -N
+ (R)
3 group, where R is a (C
1 -C
6 ) alkyl group, R2 represents a hydrogen atom or a (C
1 -C
6 )alkyl group, R3 represents: - a -(CH
2 CH
2 O)
n2 -(CH
2 )
n3 -X group, or - a –(CH
2 CH
2 O)
n4 -(CH
2 )n
5 -Y group with Y representing a -C=C-H, a -N
3 or a -Ar-(CH
2 )
n6 -(OCH
2 CH
2 )
n7 -X group, and X represents a halogen atom, a radionuclide or a -OSO
2 R' group, where R' is a CF
3 , CH
3 ,
t -Bu, Ph,
p -NO
2 Ph,
p -BrPh or
p -CH
3 Ph group, and their addition salts with pharmaceutically acceptable acids, The present invention also relates to pharmaceutical compositions comprising them and to their use in diagnosis, in particular with SPECT or PET imaging and in therapy of melanoma, via targeted radionuclide therapy.

公开(公告)号：EP2797886A2

公开(公告)日：2014-11-05

申请号：EP12815717.9

申请日：2012-12-31

申请人： Ecole Nationale Superieure de Chimie de Clermont Ferrand ,  Universite d'Auvergne Clermont I

发明人： DUCKI, Sylvie ,  BENNIS, Khalil ,  ESCHALIER, Alain ,  BUSSEROLLES, Jérôme ,  LESAGE, Florian ,  RODRIGUES, Nuno ,  VIVIER, Delphine

IPC分类号： C07D209/18 ,  C07D209/42 ,  C07C57/60 ,  C07C255/23 ,  A61K31/34 ,  A61K31/404 ,  A61K31/185 ,  A61K31/277 ,  C07D307/54 ,  A61K31/341

CPC分类号： C07C57/60 ,  C07C229/34 ,  C07C255/41 ,  C07C2601/14 ,  C07D209/18 ,  C07D209/42 ,  C07D307/54 ,  C07F9/09 ,  C07F9/12

摘要： The present invention relates to the use of compounds for the treatment or prevention of pain in mammals, in particularly in human beings, and also to a process for preparing these compounds.

摘要翻译： 本发明涉及化合物用于治疗或预防哺乳动物特别是人的疼痛的用途，还涉及制备这些化合物的方法。

公开(公告)号：EP2377883A1

公开(公告)日：2011-10-19

申请号：EP10305391.4

申请日：2010-04-15

申请人： Universite d'Auvergne Clermont I

发明人： Darfeuille-Michaud, Arlette ,  Hofman, Paul ,  Rolhion, Nathalie

IPC分类号： C07K14/47 ,  C07K16/18 ,  A61P1/00 ,  A61P37/00

CPC分类号： A61K38/164 ,  A61K38/17 ,  A61K38/177 ,  A61K39/3955 ,  A61K39/40 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/28 ,  C07K2317/76 ,  C12N15/1138 ,  C12N2310/14 ,  G01N33/6893 ,  G01N2800/065

摘要： An antagonist of the interaction between the Gp96 receptor and E. coli AIEC strains, for the prevention or treatment of inflammatory bowel disease. The antagonist is for specifically blocking or reducing the interaction between Gp96 receptor and the outer membrane vesicles (OMVs), typically the outer protein membrane OmpA of E. coli AIEC strains. The inventions provides for pharmaceutical compositions containing such an antagonist, which may be an antibody against gp96 or OmpA, or a gp96 or OmpA polypeptide. It may be combined to an antagonist of the interaction between the CEACAM6 receptor and E. coli AIEC strains, such as an anti-CEACAM6 antibody, a CEACAM6 polypeptide, or a mannoside or particle having a mannose unit. The invention also relates to a method for the diagnosis of inflammatory bowel disease, or of the determination of a predisposition of a person to develop inflammatory bowel disease.

摘要翻译： 所述的gp96受体和E之间的相互作用的拮抗剂大肠杆菌AIEC菌株，炎症性肠疾病的预防或治疗。 拮抗剂是用于特异性阻断或减少的gp96受体和外膜囊泡（OMV）通常，所述外膜蛋白E的大肠杆菌的OmpA AIEC菌株之间的相互作用。 该发明提供了药物组合物含寻求拮抗剂，这可能是多肽对抗的gp96或OmpA的或gp96的或OmpA的抗体。 它可以在受体和CEACAM6大肠杆菌之间的相互作用的拮抗剂组合，以菌株AIEC ,:如在抗CEACAM6抗体，CEACAM6多肽，或甘露侧或具有甘露糖单元的粒子。 因此本发明涉及一种用于炎症性肠疾病，或一个人的易感性的确定发展炎性肠疾病的诊断的方法。

公开(公告)号：EP2542235B1

公开(公告)日：2017-11-22

申请号：EP11712951.0

申请日：2011-03-02

申请人： Universite d'Auvergne Clermont I

发明人： BUSSEROLLES, Jérôme ,  ALLOUI, Abdelkrim ,  LAZDUNSKI, Michel ,  ESCHALIER, Alain

IPC分类号： A61K31/282 ,  A61K31/428 ,  A61K45/06 ,  A61K49/00 ,  A61P25/00 ,  A61P35/00

CPC分类号： A61K31/282 ,  A01K2227/105 ,  A01K2267/0331 ,  A61K31/428 ,  A61K45/06 ,  A61K49/0008 ,  A61K2300/00

公开(公告)号：EP2701692A1

公开(公告)日：2014-03-05

申请号：EP12717707.9

申请日：2012-04-27

申请人： Institut National de la Santé et de la Recherche Médicale (INSERM) ,  Centre Jean Perrin ,  Universite d'Auvergne Clermont I

发明人： BARTHOMEUF, Chantal ,  CHOLLET, Philippe ,  PLANCHAT, Eloise ,  CURE, Hervé

IPC分类号： A61K31/12 ,  A61K31/337 ,  A61P35/00

CPC分类号： A61K31/337 ,  A61K31/12 ,  A61K2300/00

摘要： The present invention relates to a combination of a curcuminoid and a taxane for use in the treatment of a hormone-refractory prostate cancer (HRPC) in a patient in need thereof.

公开(公告)号：EP2686863A1

公开(公告)日：2014-01-22

申请号：EP12710914.8

申请日：2012-03-19

申请人： Université Blaise Pascal Clermont II ,  Universite d'Auvergne Clermont I

发明人： BUSSIERE, William ,  ROCHETTE, David ,  ANDRE, Pascal ,  GELET, Jean-Louis

IPC分类号： H01H85/00 ,  H01H85/38

CPC分类号： H01H85/0039 ,  H01H69/01 ,  H01H69/02 ,  H01H85/08 ,  H01H85/12 ,  H01H85/165 ,  H01H85/38

摘要： The present invention relates to a process for manufacturing a fuse, comprising a step of defining the geometry of at least one fusible strip (16) employed in the fuse, in which step the following parameters are considered: a nominal current density (i16) conducted by the fusible strip (16); a nominal operating voltage of the fuse; a Joule integral corresponding, in the pre-arcing regime, to at least one part (18) of the fusible strip; and a Joule integral corresponding, in the arcing regime, to this part (18) of the fusible strip. The process is characterized in that, in this defining step, the Lorentz forces (F21-F25) acting on at least this part (18) of the fusible strip are also taken into consideration. The invention also relates to a fuse, comprising a ceramic casing and at least one fusible strip (16) placed in this casing, characterized in that it also comprises means for controlling the electromagnetic environment of the fusible strip (16) in a pre-arcing and/or a pre-arcing/arcing transition regime by amplifying or attenuating the Lorentz forces acting on at least one part of the fusible strip (16).

公开(公告)号：EP2542235A1

公开(公告)日：2013-01-09

申请号：EP11712951.0

申请日：2011-03-02

申请人： Universite d'Auvergne Clermont I

发明人： BUSSEROLLES, Jérôme ,  ALLOUI, Abdelkrim ,  LAZDUNSKI, Michel ,  ESCHALIER, Alain

IPC分类号： A61K31/282 ,  A61K31/428 ,  A61K45/06 ,  A61K49/00 ,  A61P25/00

CPC分类号： A61K31/282 ,  A01K2227/105 ,  A01K2267/0331 ,  A61K31/428 ,  A61K45/06 ,  A61K49/0008 ,  A61K2300/00

摘要： The present invention relates to the use of riluzole for treating or preventing the adverse effects linked to the delivery of anti-neoplastic agents that have neurotoxic effects, for example such as platinum salts, taxanes and periwinkle alkaloids.

摘要翻译： 本发明涉及用于治疗或预防与具有神经毒性作用的抗癌剂相关的不良反应的利鲁唑，例如铂盐，紫杉烷和长春花碱生物碱。